Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
Amer M. Zeidan, Uwe Platzbecker, Guillermo Garcia‐Manero, Mikkael A. Sekeres, Pierre Fenaux, Amy E. DeZern, Peter L. Greenberg, Michael R. Savona, Joseph G. Jurcic, Amit Verma, Ghulam J. Mufti, Rena Buckstein, Valeria Santini, Jeevan K. Shetty, Rodrigo Ito, Jennie Zhang, George Zhang, Xianwei Ha, Jay T. Backstrom, Rami S. Komrokji
Abstract
Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a randomized trial against placebo. Zeidan and colleagues report that after a median of 26 months follow-up, 27% of patients commencing luspatercept were continuing therapy. Their updated analyses confirm that a significant minority (45%) of eligible patients can achieve transfusion independence, with a median durability of 30 weeks. These longer follow-up data better quantify the incremental benefit of luspatercept over placebo.